Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
  • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
  • A61L2/18—Liquid substances
  • A61L2/186—Peroxide solutions
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
  • A23B2/00—Preservation of foods or foodstuffs, in general
  • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
  • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
  • A23B2/788—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/02—Local antiseptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
  • A61L2202/10—Apparatus features
  • A61L2202/17—Combination with washing or cleaning means
• • C—CHEMISTRY; METALLURGY
  • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
  • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
  • C02F1/00—Treatment of water, waste water, or sewage
  • C02F1/72—Treatment of water, waste water, or sewage by oxidation
  • C02F1/76—Treatment of water, waste water, or sewage by oxidation with halogens or compounds of halogens

Definitions

• the present patent application relates to a composition of hypochlorous acid and its different applications especially in the field of medicine, such as prophylactic and therapeutic treatment for infection control.
• hypochlorous acid Since 1915, following the First World War, more than 200 compounds for bacterial action were studied, among which was hypochlorous acid. It was initially detected as an oxidizing agent generated by neutrophils. It was obtained for use from seawater.
• hypochlorous acid is obtained by reacting an aqueous solution of an alkali metal hydroxide, forming drops with the gaseous chlorine to produce hypochlorous acid in steam and solid alkali metal particles; process where the molar ratios of gaseous chlorine to alkali metal hydroxide of at least 22: 1 are maintained.
• the process includes the formation of impure chlorate in chlorinated alkali metal particles.
• the hypochlorous acid produced contains about 35% to 60% by weight dissolved in concentrated chlorine of at least about 2% by weight and is substantially free of alkali metal and chlorine ions.
• OLIN CORPORATION published June 21, 1994, a process that consists in obtaining an aqueous hypochlorous acid solution having a HOCI concentration of 50% to 60% by weight, which comprises reacting an aqueous solution of an alkali metal hydroxide with 50% by weight with excess of chlorine gas, reacting them at a temperature of 80 ° C to 120 ° C, to produce a mixture of monoxide, chlorine, hypochlorous acid vapor and water vapor, chlorinated alkali metal solid particles with a chlorinated alkali metal concentration of 10 % at least.
• the Invention Patent Composition of Hypochlorous Acid and its different applications has the following advantages in relation to those found in the state of the art such as:
• hypochlorous acid composition is not toxic, it does not attack the skin.
• composition is totally biodegradable.
• the bacteriostatic power is up to 24 hr.
• hypochlorous acid a substance that has the characteristics of minimizing morbidity and mortality produced by different bacterial infections, in Comparison with normal saline, a substance most commonly used for washing the abdominal cavity and tissues.
• Hypochlorous acid is a bactericidal oxidant known primarily in aqueous solution that attacks microorganisms at the site of its production, dependent on 0 2 . It reacts in particular by modifying various high-density proteins (amino acids, lipids) that you find first in the plasma or plasma membrane proteins by inhibiting their synthesis.
• Hypochlorous acid is an unstable, highly reactive compound, it is the strongest of the halogenated hypo acids, and one of the most powerful oxidants among chlorinated oxides. It is a weak acid, with a dissociation constant of 2.9 + 10 "8 at 25 ° C, it is stable in cold, diluted and pure solutions. This acid reacts with peroxide and releases oxygen.
• Half of the protein is highly toxic to the cells, it inactivates or inhibits several endoplasmic reticulum transporter systems (glucose transport, several amino acid transporters, Na + / K + - ATPase) and, usually causes a small molecule damage, causing the cell to inflate and eventually cell death in the future. It can cause the death of very resistant bacterial spores, all types of viruses, the microbacterium with serous capsule (TB), all other vegetative bacteria, and fungi, at a concentration of 0.2% compared to other high-level microbicidal substances such as 2% alkaline glutaraldehyde or hydrogen peroxide.
• HOCI can damage isolated DNA, cell death precedes oxidation of DNA in whole cells, and the addition of myeloperoxide inhibits induced oxygen peroxide H 2 0 2 and breaks the structure of DNA.
• H 2 0 2 hydrogen peroxide
• myeloperoxidase a bactericidal agent that attacks microorganisms at the site of their proliferation, made in the immune system by nuclear polymorphic neutrophils that migrate and adhere to endothelial cells to mediate inflammation, increase permeability in the vascular endothelium, to cell participation and kill antigens.
• This substance is produced by hydrogen peroxide (H 2 0 2 ), a chlorine ion, in reaction with the enzyme myeloperoxidase.
• Myeloperoxidase converts H 2 0 2 into a reasonable microbial agent and an excellent one to HOCI and at the same time diverts the genotoxic H 2 0 2 into HOCI which is extremely toxic to the tissue, into a free protein system, but which is considerably Less toxic in vivo.
• composition of the hypochlorous acid object of the present invention patent is a hypochlorous acid solution with a content of 17g / l of available chlorine. Its physical properties are as follows:
• Chlorine (g / l) Maximum between 16 and 18
• the chemical composition is as follows:
• the tissue action of the hypochlorous acid composition is especially given by three main points:
• Antiseptic direct germicidal action like any other chlorine. This action is classically known.
• Granulant for a local increase in repair cells, since studies have shown a local increase in fibroblasts.
• composition of hypochlorous acid object of the present invention patent application, in the field of medicine, has its application mainly in:
• THERAPEUTICS 1.1.1 For antisepsis and granulation of infected tissues, abscesses, cellulite, etc. With excellent results for the healing of infectious cell tissue events subcutaneous, with open tissue, closed or without wound. 1.2.1 Ulcers of lower limbs. The surface must be kept in contact with the product. 1.3.1 Stumps and exposed surfaces. In infected cavities such as peritonitis and empyemas. 1.4.1 In infectious sinusitis and rhinitis. 1.5.1 Intra-articular for treatment of septic arthritis. Its use in orthopedic infectious events - bone.
• the surgical wound infection rate is low to 1.0% (10% - 25% in different series) for appendectomy in different studies.
• the results are shown in the following table:
• hypochlorous acid was used in ulcerative lesions of arterial and venous origin, surgical wounds, amputations both prophylactically and therapeutically, recommending to keep the affected areas moist from the liquid and its unique local use.
• Pathology biopsies were evaluated by checking the effect previously described by other authors, of local increase in fibroblasts as opposed to patients who did not use the product.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Inorganic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Wood Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Zoology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Dermatology (AREA)
• Otolaryngology (AREA)
• Pulmonology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Surgery (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Treatment Of Water By Oxidation Or Reduction (AREA)
• Medicinal Preparation (AREA)

Priority Applications (10)

Applications Claiming Priority (1)

Publications (1)

Family

ID=11004205

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (26)

Citations (4)

Family Cites Families (2)

• 2001
  • 2001-10-01 WO PCT/IB2001/002085 patent/WO2003028741A1/es not_active Ceased
  • 2001-10-01 DE DE60111430T patent/DE60111430T2/de not_active Expired - Lifetime
  • 2001-10-01 MX MXPA03007514A patent/MXPA03007514A/es active IP Right Grant
  • 2001-10-01 JP JP2003532072A patent/JP4902939B2/ja not_active Expired - Fee Related
  • 2001-10-01 EP EP01980814A patent/EP1432427B1/en not_active Expired - Lifetime
  • 2001-10-01 CN CNB018223729A patent/CN1272020C/zh not_active Expired - Fee Related
  • 2001-10-01 US US10/467,121 patent/US7323118B2/en not_active Expired - Fee Related
  • 2001-10-01 CA CA002461921A patent/CA2461921C/en not_active Expired - Lifetime
  • 2001-10-01 BR BRPI0117143-7A patent/BRPI0117143B1/pt not_active IP Right Cessation
  • 2001-10-01 ES ES01980814T patent/ES2243569T3/es not_active Expired - Lifetime

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events